EUCTR2006-004861-33-ES进行中（未招募）不适用
Ensayo clínico multinacional, abierto, aleatorizado, de grupos paralelos, para comparar la eficacia y la seguridad de insulina detemir (Levemirâ) frente a insulina humana (insulina NPH), usada en combinación con insulina aspart como insulina en bolo, en el tratamiento de mujeres embarazadas con diabetes tipo 1
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 407
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.The subject must give informed consent before any trial related activities. (Trial related activities are any procedures that would not have been performed during the normal management of the subject)
- •2.Female, age = 18 years
- •3.Type 1 diabetes treated with insulin (any regimen) for at least 12 months before randomisation
- •4.The subject is either
- •a.Planning to become pregnant in the immediate future and willing to undertake pregnancy counselling and a screening HbA1c = 9.0% (NGSP) or
- •b.Pregnant with an intrauterine singleton living foetus, GW= 8 -12 at randomisation, confirmed by a US scan and an HbA1c = 8.0% at confirmation of pregnancy
- •5.The subject must be willing to adhere to the procedures specified in the protocol, including 8-point SMPG measurements
- •6.Willingness to take (or, if pregnant at screening, have taken) folic acid before pregnancy and during the first trimester according to local guidelines
- •7.For non-pregnant subjects only: willingness to discontinue any concomitant medication, e.g. certain anti-hypertensives, like ACE-inhibitors, contraindicated in pregnancy according to local labelling prior to conception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known or suspected hypersensitivity to the trial product(s) or related products
- •2.Previous randomisation in this trial
- •3.Untreated hyper or hypothyroidism
- •4.Known or suspected abuse of alcohol or narcotics
- •5.Cardiac problems as evaluated by either:
- •a.Cardiac failure or
- •b.Diagnosis of unstable angina pectoris or
- •c.Previous myocardial infarction
- •6.Impaired renal function as evaluated by any of the following:
- •a.Diagnosis of diabetic nephropathy
- •b.S-creatinine =125 µmol/L
- •c.Macro-albuminuria, as evaluated by U-albumin:Creatinine ratio > 300 mg/g in random spot urine sample
- •7.History of severe hyperemesis gravidarum (requiring hospitalisation) according to Investigator judgement
- •8.Subject being treated or became pregnant with assistance of in-vitro fertilisation or other medical infertility treatment
- •9.Receipt of any investigational drug within 3 months prior to screening for this trial
- •10.Impaired hepatic function as evaluated by alanine aminotransferase, or alkaline phosphatase = two times the upper reference limit
- •11.Uncontrolled hypertension (systolic BP =140 mmHg and/or Diastolic BP = 90 mmHg) in the supine position
- •12.Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- •13.Proliferative retinopathy or maculopathy requiring acute treatment
- •14.Any disease or condition which the investigator feels would interfere with the trial, e.g. clinically significant gynaecological conditions
- •15.Known to be HIV positive
- •16.Known to be Hepatitis B or C positive
- •17.Any concomitant medication, e.g. certain anti-hypertensives like ACE-inhibitors, contraindicated in pregnancy.
研究者
相似试验
进行中（未招募）
1 期
Ensayo clínico multinacional, aleatorizado, doble ciego, controlado con placebo y control activo, de grupos paralelos para comparar la eficacia y seguridad, a lo largo de 24 semanas, de 3 dosis de BEA 2180 BR (50 µg, 100 µg, 200 µg) con tiotropio 5 µg y placebo administrados con el inhalador Respimat® en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC).Enfermedad Pulmonar Obstructiva Crónica (EPOC)MedDRA version: 9.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2007-001946-42-ESBoehringer Ingelheim España, S.A.1,950
进行中（未招募）
1 期
Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg,tid), administrado por vía oral, en pacientes con Hipertensión Pulmonar Tromboembólica Crónica (HPTEC). Estudio CHEST ?1 Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). - CHEST-1 StudyEUCTR2007-000072-16-ESBayer HealthCare AG
进行中（未招募）
1 期
Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg ,tid )administrado por vía oral, en pacientes con Hipertensión Arterial Pulmonar (HAP) sintomática-Estudio PATENT -1 Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-1 StudyHipertensión Arterial Pulmonar (HAP) Pulmonary Arterial Hypertension (PAH)MedDRA version: 9.1 Level: LLT Classification code 10064911 Term: Pulmonary arterial hypertensionEUCTR2008-003482-68-ESBayer HealthCare AG
进行中（未招募）
不适用
Estudio clínico multicéntrico, abierto, aleatorizado, fase IV, para evaluar la inmunogenicidad de las vacunas de polisacáridos de meningococo C conjugados con toxoide tetánico o con CRM197, administradas como dosis de refuerzo a los 14-18 meses, en niños previamente vacunados con tres dosis de vacuna conjugada con CRM197 o con dos dosis de vacuna conjugada con toxoide tetánico en los primeros siete meses de vida.”Enfermedad meningocócica por serogrupo CEUCTR2006-003525-82-ESDirección General de Salud Pública; Conselleria de Sanidad de la Comunidad Valenciana
进行中（未招募）
不适用
Ensayo clínico prospectivo, multinacional, multicéntrico, aleatorizado, doble ciego, doble simulación, que compara la eficacia y la seguridad de moxifloxacino respecto a amoxicilina/ácido clavulánico en el tratamiento de pacientes con exacerbaciones agudas de bronquitis crónica”Estudio MAESTRAL. (A prospective, multinational, multicenter, randomized, double-blind, double-dummy, controlled study comparing the efficacy and safety of moxifloxacin to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbations of chronic bronchitis: MAESTRAL (moxifloxacin in AECB superiority trial) - MAESTRAEUCTR2007-006096-37-ESBayer HealthCare AG, Leverkusen, Germany1,786